Clinical trials: Pneumonitis
Ankle Sprain, Infectious Colitis
Impact of Six Patient Information Leaflets (PIL) on Doctor Patient Communication
The purpose of this "before-after" prospective multicenter study is to assess the impact of six Patient Information Leaflets (PILs) on Doctor Patient Communication scale (DPC) and adherence scale for common acute illnesses in…
- Conditions
- Ankle Sprain, Infectious Colitis, Diverticulitis, Pyelonephritis
- Trial name
- EDIFIP (NCT02246361)
- Testing
- Patient Information Leaflet (PIL)
- Where
- 2 sites in France
- Volunteers
- 211 people
- Sponsor
- Floralis
Interstitial Lung Disease
Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
This is a 2-Part study with Part A, a double-blind, randomized, placebo-controlled, PoC study to evaluate the efficacy, safety, and tolerability of efzofitimod in patients with SSc-ILD.
- Trial name
- NCT05892614
- Testing
- efzofitimod 450 mg, efzofitimod 270 mg
- Where
- 15 sites in United States
- Volunteers
- 25 people
- Sponsor
- aTyr Pharma, Inc.
Chronic Obstructive Pulmonary Disease
Effect of ADC4022 Co-Administered With Budesonide on Pulmonary Inflammation in Subjects With Moderate to Severe COPD
The purpose of this study is to assess the tolerability and efficacy of inhaled theophylline (ADC4022) on markers of pulmonary inflammation (white blood cells) in induced sputum and in bronchial biopsy samples in subjects with…
- Trial name
- NCT00634413
- Testing
- Theophylline - ADC4022, Budesonide
- Where
- 8 sites in Poland, United Kingdom
- Volunteers
- 91 people
- Sponsor
- Pulmagen Therapeutics
Idiopathic Pulmonary Fibrosis
Evaluate the Safety and Efficacy of FG-3019 (Pamrevlumab) in Participants With Idiopathic Pulmonary Fibrosis (IPF)
To evaluate the safety and tolerability of pamrevlumab in participants with IPF, and the efficacy of pamrevlumab in slowing the loss of forced vital capacity (FVC) and the progression of IPF in these participants.
- Trial name
- NCT01890265
- Testing
- Pamrevlumab, Sub-Study: Pirfenidone, Sub-Study: Nintedanib
- Where
- 42 sites in United States, Australia and 5 more
- Volunteers
- 160 people
- Sponsor
- Kyntra Bio
Chronic Obstructive Pulmonary Disease
A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD
The purpose of this study is to assess the efficacy and safety of verekitug (UPB-101) in participants with moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD), an inflammatory lung disease.
- Trial name
- NCT06981078
- Testing
- Verekitug
- Where
- 242 sites in United States, Argentina and 21 more
- Volunteers
- 666 people
- Sponsor
- Upstream Bio Inc.
Pulmonary Disease, Chronic Obstructive
Evaluate the Effects of the Drug (SB-656933-AAA) on the Body After a Single Dose in Subjects Who Have Inhaled Ozone
A study to evaluate the effect of SB-656933-AAA on the body after a single dose in subjects who have been challenged with ozone.
- Trial name
- NCT00551811
- Testing
- SB-656933-AAA
- Where
- Germany
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Alveolitis Extrinsic Allergic, Pulmonary Fibrosis
Pirfenidone in the Chronic Hypersensitivity Pneumonitis Treatment
The Chronic Hypersensitivity Pneumonitis (HP), is an inflammatory disease who has an evolution to develop progressive interstitial fibrosis, who cause the death of the patient.
- Trial name
- Picheon (NCT02496182)
- Testing
- Pirfenidone
- Where
- Mexico
- Volunteers
- 60 people
- Sponsor
- Grupo Medifarma, S. A. de C. V.
Pneumonia
A Study to Compare the Efficacy and Safety of Levofloxacin in the Treatment of Children With Community-acquired Pneumonia in the Hospital or Outpatient Setting
The purpose of this study is to determine the safety and efficacy of levofloxacin in the treatment of children with community acquired pneumonia.
- Trial name
- NCT00034736
- Testing
- Levofloxacin
- Volunteers
- 691 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Healthy Subjects (Indication: Asthma)
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Elarekibep in Healthy Japanese Subjects
This study will assess the safety, tolerability and pharmacokinetics (PK) of elarekibep after single and multiple doses given twice daily (BID) by inhalation or intravenous (IV) in healthy Japanese subjects compared with placebo.
- Trial name
- NCT05794672
- Testing
- Elarekibep
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- AstraZeneca
Covid19
LLLT Treatment of Lung Inflammation in COVID-19
To determine if a reduction of pneumonic inflammation occurs after treatment with Low-Level Laser Therapy (LLLT) applying red-light technology in the respiratory system of COVID-19 patients suffering from acute viral pneumonia.
- Trial name
- NCT04524715
- Testing
- Non-invasive red LLLT treatment to chest of patient.
- Where
- United States
- Sponsor
- Ward Photonics LLC
Idiopathic Pulmonary Fibrosis
A 2-Part, Phase 2 Open-label and Crossover Study of Belumosudil for Treatment of Idiopathic Pulmonary Fibrosis
This Phase 2 study is to be conducted to evaluate the safety, tolerability, and activity of 400 mg of belumosudil orally (PO) once-daily (QD) compared to Best Supportive Care (BSC) in male and postmenopausal/surgically sterilized…
- Trial name
- NCT02688647
- Testing
- Belumosudil, BSC
- Where
- 10 sites in United States
- Volunteers
- 76 people
- Sponsor
- Kadmon Corporation, LLC
Unresectable Stage III NSCLC
Mobile Devices to Detect Early Pneumonitis in Stage III NSCLC Patients on Durvalumab.
A study of whether mobile devices can improve the detection of pulmonary AEs (including pneumonitis) in stage III NSCLC patients post-CRT, while on durvalumab.
- Trial name
- ON TRAX (NCT04381494)
- Testing
- Multiparametric Mobile Technology
- Where
- 18 sites in United States
- Volunteers
- 40 people
- Sponsor
- AstraZeneca
COPD
Chronic Obstructive Pulmonary Disease (COPD) Biomarker Identification Study
Chronic obstructive pulmonary disease (COPD) is a common inflammatory disease of the airway affecting approximately 10% of individuals aged 40 years or more with a smoking history.
- Trial name
- NCT01780298
- Where
- United Kingdom
- Volunteers
- 252 people, healthy volunteers welcome
- Sponsor
- Philip Morris Products S.A.
Covid19, COVID-19 Lower Respiratory Infection
In-patient COVID-19 Study of Intranasal Foralumab
This is a Phase 2, randomized, placebo-controlled, double-blind, proof-of-concept study of intranasal foralumab in hospitalized subjects with severe COVID-19 and pulmonary inflammation.
- Conditions
- Covid19, COVID-19 Lower Respiratory Infection, COVID-19 Respiratory Infection
- Trial name
- NCT04983446
- Testing
- Foralumab
- Sponsor
- Tiziana Life Sciences LTD
Pulmonary Arterial Hypertension, Pulmonary Hypertension
Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT
This study assesses the safety and efficacy of bardoxolone methyl relative to placebo in patients with pulmonary hypertension to determine the recommended dose range, evaluate the change from baseline in 6-minute walk distance…
- Conditions
- Pulmonary Arterial Hypertension, Pulmonary Hypertension, Interstitial Lung Disease, Idiopathic Interstitial Pneumonia
- Trial name
- NCT02036970
- Testing
- Bardoxolone methyl
- Where
- 32 sites in United States, Germany
- Volunteers
- 166 people
- Sponsor
- Biogen
Pulmonary Disease, Chronic Obstructive
Endotoxin Challenge Study For Healthy Men and Women
The proposed study will examine the effect of pre-treatment with inhaled GSK256066 using a lung inflammation model induced by bronchoscopic instillation of bacterial endotoxin (lipopolysaccharide, LPS) in healthy volunteers.Data…
- Trial name
- NCT00515268
- Testing
- GSK256066
- Where
- Germany
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Radiation Pneumonitis, Lung Cancer
Phase 2a Clinical Trial to Evaluate the Efficacy and Safety of HL301 on Radiation Pneumonitis in Non-small Cell Lung Cancer Patients
The purpose of this clinical trial is to evaluate the safety when HL301 is administered to unresectable non-small cell lung cancer patients who receive chemoradiotherapy with Paclitaxel and Carboplatin and to search for a…
- Trial name
- NCT04632342
- Testing
- HL301 tablet 300mg
- Where
- South Korea
- Volunteers
- 87 people
- Sponsor
- Hanlim Pharm. Co., Ltd.
Cystic Fibrosis
Pro-resolving Effect of MAG-DHA in Cystic Fibrosis (PREMDIC)
Monoglyceride of DHA (DHA-MAG) is a lipid compound for which intestinal absorption would increase the ratio DHA / arachidonic acid (AA) and promote the synthesis of specific metabolites involved in the resolution of inflammation.
- Trial name
- PREMDIC (NCT02518672)
- Testing
- MAG-DHA
- Where
- Canada
- Volunteers
- 11 people
- Sponsor
- SCF Pharma
Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis
A randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of 2 doses of inhaled pirfenidone (AP01) versus placebo on top of standard of care in participants with PPF over 52 weeks.
- Conditions
- Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, Pulmonary Fibrosis Secondary to Systemic Sclerosis, Pulmonary Fibrosis, Interstitial Lung Disease
- Trial name
- NCT06329401
- Testing
- AP01
- Where
- 154 sites in United States, Argentina and 12 more
- Volunteers
- 398 people
- Sponsor
- Avalyn Pharma Inc.
Non-Small Cell Lung Cancer
Study of Non-Small Cell Lung Cancer Patients in the US Receiving Standard-of-Care and Initiating an Approved Therapy With Risk of Pneumonitis/ILD
This is an observational, prospective, multicenter study conducted in the US to gather evidence in the context of lung cancer to complement the development of a digital solution.
- Trial name
- LOOP (NCT06192004)
- Testing
- None (Observational Study)
- Where
- 23 sites in United States
- Volunteers
- 83 people
- Sponsor
- AstraZeneca